To conduct a quantitative review of the literature to compare the short-term efficacy of pharmacotherapy and behavioural therapy in primary insomnia.
Results of the review
Twenty-one studies with a total of 470 participants satisfied the inclusion criteria: 7 studies (203 participants) evaluated only pharmacological therapies, 13 studies (232 participants) evaluated only behavioural interventions, and one study (35 participants) compared pharmacotherapy with behavioural therapy. The studies spanned the years from 1979 to 1999.
There were no differences in the patients' age, gender and pre-treatment means for sleep latency, number of awakenings, wake time after sleep onset, total sleep time and subjective sleep quality between the pharmacotherapy and behavioural treatment (p>0.05). As expected, the duration of behavioural treatment was significantly longer than pharmacotherapy (t=-4.38, d.f.=26.49, p<0.001). These comparisons indicated that the two treatment populations were similar.
Sleep latency was reduced by 30% with the pharmacological treatment, compared with 43% for the behavioural interventions (95% confidence interval, CI, for the difference between ESs: 0.17, 1.04). Both interventions reduced the number of awakenings each night by approximately one (95% CI for the difference between ESs: -1.24, 1.5). Wake time after sleep onset was reduced by 46% with pharmacotherapy and by 56% with behaviour therapy. Total sleep time was increased by 12% and 6% with pharmacotherapy and behaviour therapy, respectively (95% CI for the difference between ESs: -0.25, 1.01). Sleep quality was improved by 20% with pharmacotherapy and by 28% with behaviour therapy (95% CI for the difference between ESs: -1.70, 1.22). The mean ES for all five outcome variables was 0.87 for pharmacotherapy and 0.96 for behaviour therapy. Independent t-tests for unequal variances were calculated for the five individual sleep variables, in order to compare the weighted ESs for pharmacotherapy and behavioural therapy. Levine's test indicated that behavioural therapy had greater variability in weighted ESs for sleep latency than pharmacological studies (F=8.05, d.f.=20.6, p=0.01). selection bias. There was no attempt to identify unpublished or grey literature, and publication bias was not assessed.
The validity of the primary studies does not appear to have been assessed, which may have implications for the reliability of the findings of the review. The authors identified the following limitations of their review: patients undergoing behavioural interventions have more contact with their clinicians, and this greater access to clinician support may affect the efficacy of the intervention; patients were self-selected, therefore, it cannot be concluded that the treatments yield comparable gains across all patients; and subjective measures of outcome were used.
The tables of the primary data were adequate, and the synthesis of the data appears to have been appropriate. Heterogeneity was assessed for participant characteristics and treatment duration. The two treatment populations were similar; there were no differences in the participants' gender, age and pre-treatment means for sleep latency, number of awakenings, wake time after sleep onset, total sleep time, and subjective sleep quality between the groups (p>0.05).
The authors' conclusions should be interpreted with some caution given the potential for selection bias and the lack of a validity assessment.
Implications of the review for practice and research
Practice: The authors state that the present study demonstrates that behaviour therapy for persistent primary insomnia is as effective as pharmacotherapy in the short-term. In addition, that pharmacotherapies may be selected when immediate symptom reduction is the primary consideration, and behavioural treatment may be indicated when pharmacotherapies are contraindicated (e.g. because of potential drug interactions or a history of substance abuse). The authors also state that the difference in treatment cost is likely to be a major consideration since even the most expensive sedative hypnotics, in the short run, do not rival the costs of behaviour therapy. Finally, they state that in the instances when patients and clinicians do not wish to use hypnotics to treat persistent insomnia, practitioners should strongly consider referring patients for behaviour therapy, and that some should consider training in behavioural therapy.
Research: The authors state that more research is required before an overall cost-benefit analysis can be conducted. 
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